Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

Specimen Handling 219Magnetic Resonance Spectroscopy 195pembrolizumab 186Carboplatin 161Cisplatin 131Biopsy 129Nivolumab 121Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 98Dexamethasone 87durvalumab 85atezolizumab 70Rituximab 66Lenalidomide 65Radiation 64Doxorubicin 63Pemetrexed 62Bevacizumab 58Docetaxel 57Etoposide 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 47Vincristine 45Radiosurgery 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Diffusion Tensor Imaging × 90 days × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡